409 related articles for article (PubMed ID: 29497277)
1. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
Dean M; Sung VW
Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
[TBL] [Abstract][Full Text] [Related]
2. Deutetrabenazine for the treatment of Huntington's chorea.
Bashir H; Jankovic J
Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
[TBL] [Abstract][Full Text] [Related]
3. Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.
Heo YA; Scott LJ
Drugs; 2017 Nov; 77(17):1857-1864. PubMed ID: 29080203
[TBL] [Abstract][Full Text] [Related]
4. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946
[No Abstract] [Full Text] [Related]
5. Deutetrabenazine in the treatment of Huntington's disease.
Richard A; Frank S
Neurodegener Dis Manag; 2019 Feb; 9(1):31-37. PubMed ID: 30624137
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect.
Schneider F; Stamler D; Bradbury M; Loupe PS; Hellriegel E; Cox DS; Savola JM; Gordon MF; Rabinovich-Guilatt L
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):647-659. PubMed ID: 33038289
[TBL] [Abstract][Full Text] [Related]
7. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
Claassen DO; Philbin M; Carroll B
Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641
[No Abstract] [Full Text] [Related]
8. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.
Claassen DO; Carroll B; De Boer LM; Wu E; Ayyagari R; Gandhi S; Stamler D
J Clin Mov Disord; 2017; 4():3. PubMed ID: 28265459
[TBL] [Abstract][Full Text] [Related]
9. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 29024264
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience With Deutetrabenazine for Huntington Disease Chorea.
Curtis K; Sung V
J Clin Pharmacol; 2024 Feb; 64(2):178-181. PubMed ID: 37565322
[TBL] [Abstract][Full Text] [Related]
11. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
Paton DM
Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387
[TBL] [Abstract][Full Text] [Related]
12. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.
Frank S; Stamler D; Kayson E; Claassen DO; Colcher A; Davis C; Duker A; Eberly S; Elmer L; Furr-Stimming E; Gudesblatt M; Hunter C; Jankovic J; Kostyk SK; Kumar R; Loy C; Mallonee W; Oakes D; Scott BL; Sung V; Goldstein J; Vaughan C; Testa CM;
JAMA Neurol; 2017 Aug; 74(8):977-982. PubMed ID: 28692723
[TBL] [Abstract][Full Text] [Related]
13. Deuterium Tetrabenazine for Tardive Dyskinesia.
Cummings MA; Proctor GJ; Stahl SM
Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):214-220. PubMed ID: 29341821
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers.
Schneider F; Bradbury M; Baillie TA; Stamler D; Hellriegel E; Cox DS; Loupe PS; Savola JM; Rabinovich-Guilatt L
Clin Transl Sci; 2020 Jul; 13(4):707-717. PubMed ID: 32155315
[TBL] [Abstract][Full Text] [Related]
15. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
Peckham AM; Nicewonder JA
J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
[TBL] [Abstract][Full Text] [Related]
16. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
; Frank S; Testa CM; Stamler D; Kayson E; Davis C; Edmondson MC; Kinel S; Leavitt B; Oakes D; O'Neill C; Vaughan C; Goldstein J; Herzog M; Snively V; Whaley J; Wong C; Suter G; Jankovic J; Jimenez-Shahed J; Hunter C; Claassen DO; Roman OC; Sung V; Smith J; Janicki S; Clouse R; Saint-Hilaire M; Hohler A; Turpin D; James RC; Rodriguez R; Rizer K; Anderson KE; Heller H; Carlson A; Criswell S; Racette BA; Revilla FJ; Nucifora F; Margolis RL; Ong M; Mendis T; Mendis N; Singer C; Quesada M; Paulsen JS; Brashers-Krug T; Miller A; Kerr J; Dubinsky RM; Gray C; Factor SA; Sperin E; Molho E; Eglow M; Evans S; Kumar R; Reeves C; Samii A; Chouinard S; Beland M; Scott BL; Hickey PT; Esmail S; Fung WL; Gibbons C; Qi L; Colcher A; Hackmyer C; McGarry A; Klos K; Gudesblatt M; Fafard L; Graffitti L; Schneider DP; Dhall R; Wojcieszek JM; LaFaver K; Duker A; Neefus E; Wilson-Perez H; Shprecher D; Wall P; Blindauer KA; Wheeler L; Boyd JT; Houston E; Farbman ES; Agarwal P; Eberly SW; Watts A; Tariot PN; Feigin A; Evans S; Beck C; Orme C; Edicola J; Christopher E
JAMA; 2016 Jul; 316(1):40-50. PubMed ID: 27380342
[TBL] [Abstract][Full Text] [Related]
17. Deutetrabenazine in the treatment of tardive dyskinesia.
Niemann N; Jimenez-Shahed J
Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
Niemann N; Jankovic J
Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
[TBL] [Abstract][Full Text] [Related]
19. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
Citrome L
Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
[TBL] [Abstract][Full Text] [Related]
20. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
Koch J; Shi WX; Dashtipour K
Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
